ArticleNanoscale research letters2015
Novel Functionalized Selenium Nanoparticles for Enhanced Anti-Hepatocarcinoma Activity In vitro.
Article in Nanoscale research letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 80 citations in OpenAlex.
- Single cell ICP-MS for the assessment of potential nephroprotectors against cisplatin.Mikrochimica acta · 2025Article
- The role and mechanism of selenium in the prevention and progression of hepatocellular carcinoma.Frontiers in oncology · 2025Review
- Resveratrol/Selenium Nanocomposite with Antioxidative and Antibacterial Properties.Nanomaterials (Basel, Switzerland) · 2024Article
- Components of the JNK-MAPK pathway play distinct roles in hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2023Article
- Exploring Antibacterial Activity and Bacterial-Mediated Allotropic Transition of Differentially Coated Selenium Nanoparticles.ACS applied materials & interfaces · 2023Article
- Unveiling the nanotoxicological aspects of Se nanomaterials differing in size and morphology.Bioactive materials · 2023Article
- Biogenic Selenium Nanoparticles and Their Anticancer Effects Pertaining to Probiotic Bacteria-A Review.Antioxidants (Basel, Switzerland) · 2022Review
- Correction to: Novel Functionalized Selenium Nanoparticles for Enhanced Anti-Hepatocarcinoma Activity In vitro.Nanoscale research letters · 2022Article
- Application of Green Gold Nanoparticles in Cancer Therapy and Diagnosis.Nanomaterials (Basel, Switzerland) · 2022Review
- Facile Synthesis of Gold Nanoparticles for Anticancer, Antioxidant Applications, and Photocatalytic Degradation of Toxic Organic Pollutants.ACS omega · 2022Article
- Modulation of the p38 MAPK Pathway by Anisomycin Promotes Ferroptosis of Hepatocellular Carcinoma through Phosphorylation of H3S10.Oxidative medicine and cellular longevity · 2022Article
- Lentinan-functionalized selenium nanoparticles induce apoptosis and cell cycle arrest in human colon carcinoma HCT-116 cells.Frontiers in nutrition · 2022Article
- Antioxidant stress and anticancer activity of peptide‑chelated seleniumInternational journal of molecular medicine · 2021Article
- Polymer Nanocomposites of Selenium Biofabricated Using Fungi.Molecules (Basel, Switzerland) · 2021Review
- Enzyme-Loaded Flower-Shaped Nanomaterials: A Versatile Platform with Biosensing, Biocatalytic, and Environmental Promise.Nanomaterials (Basel, Switzerland) · 2021Review
- Synthesis of silymarin-selenium nanoparticle conjugate and examination of its biological activity in vitro.ADMET & DMPK · 2021Article
- Green Synthesis of Selenium Nanoparticles by CyanobacteriumBioMed research international · 2021Article
- Review
- Comparative Study of the Antimicrobial Activity of Selenium Nanoparticles With Different Surface Chemistry and Structure.Frontiers in bioengineering and biotechnology · 2020Article
- Folate-targeted selenium nanoparticles deliver therapeutic siRNA to improve hepatocellular carcinoma therapy.RSC advances · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selenium nanoparticles loaded with an anticancer molecule offer a new strategy for cancer treatment. In the current study, anisomycin-loaded functionalized selenium nanoparticles (SeNPs@Am) have been made by conjugating anisomycin to the surface of selenium nanoparticles to improve anticancer efficacy. The prepared nanoparticles were fully characterized by transmission electronic microscopy, energy dispersive X-ray spectroscopy, Fourier-transformed infrared spectroscopy, and X-ray photoelectron spectroscopy. The results showed that anisomycin was successfully conjugated with selenium nanoparticles. The size of particles could be effectively regulated through altering the reaction concentrations of sodium selenite and anisomycin. The SeNPs@Am particles (56 nm) exhibited the greatest capacity for cellular uptake. The further study showed that SeNPs@Am entered human hepatocellular carcinoma HepG2 cells in a dose or time-dependent manner via macropinocytosis and clathrin-mediated endocytosis pathways. SeNPs@Am significantly inhibited HepG2 cell proliferation with the low cytotoxicity against normal cells, and dramatically precluded the aggression and migration of HepG2 cells. It also arrested the cell cycle progression at the G0/G1 phase through the activation of the cyclin-dependent kinase inhibitors with inhibition of CDK-2 and ICBP90, and induced the cell apoptosis through activating the caspase cascade signaling in HepG2 cells, markedly superior to anisomycin alone. The findings indicate that SeNPs@Am may be a promising drug for hepatocellular carcinoma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.